HPV Information Center
The approval of the expanded age range was based on data from a clinical trial which evaluated the efficacy of Gardasil (quadrivalent human papillomavirus recombinant vaccine) in 3253 women 27-45 years of age with a median duration of follow-up of 3.5 years post-dose 3.
14 million need to receive two doses of vaccine to reach goal of 80% vaccination by 2026.
From 2008 to 2015, both cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ rates and cervical cancer screening declined in women age 18 to 24 years.
Cytology recommended every 3 years from age 21; different screening options from age 30 to 65.
Researchers sought to identify parental predictors of HIV vaccination in low-income adolescent Hispanic girls.
No substantive or significant associations between HPV legislation and adolescent sexual behaviors.
Less than a year following the initial direct-to-tumor vaccine injection, all treated tumors disappeared.
Vaccinated women and girls living with HIV may be at greater risk for HPV vaccine failure compared with women and girls without HIV.
Use of primary HPV testing results in significantly lower odds of CIN3 compared with cytology testing
Regardless of age, favorable survival conferred by an HPV-positive tumor status